🇺🇸 FDA

Intelligence · Clinical Pipeline

R&D Pipeline Programs

ClinicalTrials.gov programs linked to pharma sponsors — phase, modality, and trial IDs for BD and competitive intelligence.

Programs indexed
20,548
Companies
1,769
Drugs tracked
4,797

Quick answer

NovaPharmaNews tracks 20,548 pharmaceutical R&D pipeline programs sourced from ClinicalTrials.gov, linked to sponsor companies. Each profile includes development phase, modality, trial status, NCT identifiers, and indication text — searchable for business development and competitive intelligence.

4,838 results for “SP” Clear

  1. NaCl 0.9%, GAMMA-OH 200 mg/ml, solution injectable (IV)

    Pari Pharma GmbH

    The study population includes adult ICU patients with a hospitalization of more than 48 hours. We have chosen to include patients with or without mechanical ventilation, as sleep disorders affect all ICU patients after 48 hours.

    phase 2 small molecule active

    1 trial

  2. Nab-paclitaxel

    Xiyuan Hospital of China Academy of Chinese Medical Sciences

    Head and Neck Squamous Cell Carcinoma

    phase 2 small molecule completed

    1 trial

  3. Nab-paclitaxel Combined With Cadonilimab (AK104)

    Xiyuan Hospital of China Academy of Chinese Medical Sciences

    Gastric Cancer

    phase 2 small molecule active

    1 trial

  4. Nabiximols

    Jazz Pharmaceuticals Ireland Limited

    NMO Spectrum Disorder

    phase 2 small molecule terminated

    1 trial

  5. Nebivolol Ophthalmic Suspension 1 Percent

    Summit Therapeutics

    Open-Angle Glaucoma

    phase 2 small molecule completed

    1 trial

  6. Nemolizumab

    Galderma Australia Pty Ltd

    Atopic Dermatitis

    phase 2 small molecule active

    1 trial

  7. Neoadjuvant Chemotherapy

    Xiangya Hospital of Central South University

    High-Grade Upper Tract Urothelial Carcinoma

    phase 2 small molecule completed

    1 trial

  8. Neoadjuvant Chemotherapy (NACT)

    The First People's Hospital of Lianyungang

    HR+/HER2- Breast Cancer

    phase 2 small molecule active

    1 trial

  9. Neoadjuvant Chemotherapy combined with Neoadjuvant Radiotherapy

    The First People's Hospital of Lianyungang

    Breast Cancer

    phase 2 other active

    1 trial

  10. Neoadjuvant Sugemalimab + Chemotherapy Followed by Adjuvant Sugemalimab

    Xiyuan Hospital of China Academy of Chinese Medical Sciences

    Lung Cancer (NSCLC)

    phase 2 small molecule active

    1 trial

  11. Neoadjuvant Therapy

    The First People's Hospital of Lianyungang

    Gastric Cancer

    phase 2 other active

    1 trial

  12. Neoadjuvant therapy: TCbHPy

    The First People's Hospital of Lianyungang

    Breast Cancer

    phase 2 other active

    1 trial

  13. Neoantigen specific TCR-T cell drug product

    Alaunos Therapeutics

    Gynecologic Cancer

    phase 2 mab terminated

    1 trial

  14. Neu2000KWL

    Xiyuan Hospital of China Academy of Chinese Medical Sciences

    Stroke

    phase 2 small molecule completed

    1 trial

  15. NeuroEPO

    Xiyuan Hospital of China Academy of Chinese Medical Sciences

    Parkinson Disease

    phase 2 small molecule completed

    1 trial

  16. Nimenrix powder and solvent for solution for injection in pre-filled syringe Meningococcal groups A, C, W-135 and Y conjugate vaccine, Prevenar 13 suspension for injection pneumococcal polysaccharide conjugate vaccine (13-valent, adsorbed), Rotarix oral suspension in pre-filled oral applicator Rotavirus vaccine, live, Infanrix hexa, Powder and suspension for suspension for injection. Diphtheria (D), tetanus (T), pertussis (acellular, component) (Pa), hepatitis B (rDNA) (HBV), poliomyelitis (inactivated) (IP

    GlaxoSmithKline

    Infections, Meningococcal

    phase 2 small molecule active

    1 trial

  17. Nimotuzumab

    The First People's Hospital of Lianyungang

    Esophageal Neoplasms

    phase 2 small molecule active

    1 trial

  18. Nimotuzumab

    The First People's Hospital of Lianyungang

    Esophageal Squamous Cell Carcinoma

    phase 2 small molecule active

    1 trial

  19. Nimotuzumab + SHR-1210

    The First People's Hospital of Lianyungang

    Esophageal Squamous Cell Carcinoma

    phase 2 small molecule active

    1 trial

  20. Nimotuzumab combined with chemoradiotherapy

    The First People's Hospital of Lianyungang

    Pancreatic Cancer Non-resectable

    phase 2 small molecule active

    1 trial

  21. Nintedanib,Dextromethorphan

    The First People's Hospital of Lianyungang

    Idiopathic Pulmonary Fibrosis (IPF)

    phase 2 small molecule active

    1 trial

  22. Niraparib

    Xiyuan Hospital of China Academy of Chinese Medical Sciences

    Ovarian Cancer

    phase 2 small molecule active

    1 trial

  23. Niraparib

    Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University

    Platinum-resistant Recurrent Clear Cell Ovarian Cancer

    phase 2 small molecule completed

    1 trial

  24. Nitric Oxide

    Xiyuan Hospital of China Academy of Chinese Medical Sciences

    Pressure Ulcer

    phase 2 small molecule active

    1 trial

Frequently asked questions

What is the NovaPharmaNews pipeline directory?

It is a searchable index of 20,548 clinical development programs grouped by sponsor company, with phase (Phase 1–3), modality, trial status, and linked NCT IDs from ClinicalTrials.gov.

Where does pipeline data come from?

Program records are derived from ClinicalTrials.gov and linked to NovaPharmaNews company profiles. Trial status and phase reflect registry data at last sync — verify on ClinicalTrials.gov before investment or partnering decisions. See our data sources page for attribution.

How do I find pipeline programs by company or phase?

Use the search box to match program name, indication, company name, or slug. Results are ordered with late-stage (Phase 3) programs first. Open any row to view the full program profile under its sponsor company.

Data attribution and licensing: Data sources